ReviewNature reviews. Endocrinology2023
Current and future pharmacotherapies for obesity in children and adolescents.
Review in Nature reviews. Endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Long-term administration of liraglutide for weight management in pediatric patients under 18 years: evidence from 7 randomized controlled trials.Pediatric research · 2026Pooled it
- Efficacy and safety of GLP-1 receptor agonists for adolescents and children with obesity: a meta-analysis of randomized controlled trials.BMC endocrine disorders · 2026Pooled it
- Glucagon-Like Peptide-1 Receptor Agonists and Risk of Venous Thromboembolism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of the American Heart Association · 2025Pooled it
- GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application.International journal of molecular sciences · 2026Review
- Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review.World journal of clinical pediatrics · 2026Review
- Differences in body composition and physical activity in youth with obesity who report pain.Obesity pillars · 2026Article
- Adipocyte-Derived Leptolin Enhances Energy Expenditure and Prevents Obesity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Outcomes of Metabolic and Bariatric Surgery Among Adolescents and Young Adults in Southern Louisiana.Obesity surgery · 2026Article
- Efficacy and safety of glucagon-like peptide-1 (GLP-1) agonists in pediatric obesity: A systematic review and meta-analysis.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026Article
- Management of Childhood Obesity.International journal of molecular sciences · 2026Review
- Odds of Developing Overweight or Obesity Increase with Height Decile in Tall Healthy Weight Kindergarteners: Longitudinal Results from the West Virginia Coronary Artery Risk Detection In Appalachian Communities (WV CARDIAC) Project.Journal of pediatrics. Clinical practice · 2026Article
- Obesity Phenotyping in Children and Adolescents: Next Steps Towards Precision Medicine in Pediatric Obesity.Nutrients · 2026Review
- Non-nutritive sweeteners and body weight in children with type 1 and type 2 diabetes: a critical narrative review of current evidence, methodological challenges, biological mechanisms, and clinical implications.Frontiers in nutrition · 2026Review
- Weight management for overweight and obese adolescents: Current treatments.Asia Pacific journal of clinical nutrition · 2025Review
- Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.Journal of endocrinological investigation · 2025Review
- Real-World Use of Phentermine and Topiramate for Adolescent Obesity: Retrospective Effectiveness and Safety Analysis.Childhood obesity (Print) · 2025Article
- Article
- Bridging the gap in obesity research: A consensus statement from the European Society for Clinical Investigation.European journal of clinical investigation · 2025Review
- Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.Lancet (London, England) · 2025Article
- Assessment and medical management of weight regain after adolescent metabolic and bariatric surgery: a narrative review.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a common chronic disease in children and adolescents and its prevalence is increasing worldwide. The causes are multifactorial but involve biological predisposition towards a specific body-weight set point and defended adipose tissue mass converging with an obesogenic environment. Comprehensive treatment of paediatric obesity includes lifestyle modification therapy, anti-obesity medications (AOMs) and/or metabolic surgery. Lifestyle modification therapy used alone produces fairly modest weight loss for most youth with obesity. The emergence of new AOMs has changed the landscape of paediatric weight management, improving the outlook for youth with obesity. This Review briefly highlights obesity development pathways in youth and the role that pharmacotherapy can play in counteracting these pathophysiological forces. Here, results from adolescent AOM clinical trials published since 2020 are reviewed, including the safety, efficacy and tolerability of the newest treatments (glucagon-like peptide 1 receptor agonists and phentermine-topiramate). The importance of a comprehensive and chronic care model, including both lifestyle modification and ongoing pharmacotherapy, will be discussed in the context of maximizing long-term health outcomes. Finally, insight will be provided into the emerging pipeline of AOMs (for example, incretin receptor co-agonists and tri-agonists) and how future therapies might fundamentally change the prognosis for youth with obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.